![]() ![]() EGF then activates the EGFR signaling pathway, contributing to cisplatin resistance. TRPV1 promotes secretory autophagy, a process that leads to the secretion of epidermal growth factor (EGF). They found that NANOG activates transient receptor potential vanilloid 1 (TRPV1), which is responsible for causing neuropathic pain. This led them to conclude that overactive EGFR triggers resistance mechanisms, resulting in decreased drug efficacy in tumor cells.įurthermore, the team identified NANOG, a transcription factor associated with resistance, metastasis, and stem cell-like properties in cancer cells. The researchers conducted experiments on cervical cancer cell lines and found that the cisplatin-resistant cells exhibited overactivated EGFR signaling compared to cisplatin-sensitive cells. ![]() They analyzed the transcriptome of cervical cancer patients who had undergone surgery and discovered that elevated activity scores of epidermal growth factor receptor (EGFR) were associated with poor Actually survival in patients treated with cisplatin.ĮGFR is a protein involved in cell signaling, and its deregulation can lead to uncontrolled cell growth and tumor formation. In a recent study published in Nature Communications, Professor Tae Woo Kim and his team from Korea Medical University investigated the pathways that contribute to cisplatin resistance in cervical cancer. Overcoming these challenges is crucial for improving treatment outcomes in cervical cancer patients. While cisplatin, a potent chemotherapeutic agent, has been used to treat cervical cancer, its continued use can lead to the development of drug resistance and other side effects. Cervical cancer is a devastating disease that affects many women worldwide. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |